Compare INSP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | VCEL |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2018 | 1996 |
| Metric | INSP | VCEL |
|---|---|---|
| Price | $70.41 | $39.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $62.80 | $60.57 |
| AVG Volume (30 Days) | ★ 696.7K | 397.9K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | $82,050,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $21.71 |
| Revenue Next Year | $3.95 | $16.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 62.18 | 16.45 |
| 52 Week Low | $38.91 | $28.95 |
| 52 Week High | $147.03 | $49.32 |
| Indicator | INSP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 47.72 |
| Support Level | $55.37 | $37.78 |
| Resistance Level | $78.80 | $41.12 |
| Average True Range (ATR) | 3.41 | 1.17 |
| MACD | -0.66 | 0.26 |
| Stochastic Oscillator | 28.77 | 69.65 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.